{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:03:16Z","timestamp":1793120596969,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T00:00:00Z","timestamp":1658275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T00:00:00Z","timestamp":1658275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Virol"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s00705-022-05530-7","type":"journal-article","created":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T05:02:58Z","timestamp":1658293378000},"page":"2181-2191","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Immunogenic properties of SARS-CoV-2 inactivated by ultraviolet light"],"prefix":"10.1007","volume":"167","author":[{"given":"A. V.","family":"Gracheva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. R.","family":"Korchevaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu. I.","family":"Ammour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. I.","family":"Smirnova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O. S.","family":"Sokolova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. S.","family":"Glukhov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. V.","family":"Moiseenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. V.","family":"Zubarev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. V.","family":"Samoilikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. A.","family":"Leneva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O. A.","family":"Svitich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. V.","family":"Zverev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeny B.","family":"Faizuloev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,20]]},"reference":[{"key":"5530_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2021-140654","author":"AI Francis","year":"2021","unstructured":"Francis AI, Ghany S, Gilkes T et al (2021) Review of COVID-19 vaccine subtypes, efficacy and geographical distributions. Postgrad Med J. https:\/\/doi.org\/10.1136\/postgradmedj-2021-140654","journal-title":"Postgrad Med J"},{"key":"5530_CR2","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2021.10843","author":"G Marfe","year":"2021","unstructured":"Marfe G, Perna S, Shukla AK (2021) Effectiveness of COVID-19 vaccines and their challenges (Review). Exp Ther Med. https:\/\/doi.org\/10.3892\/etm.2021.10843","journal-title":"Exp Ther Med"},{"key":"5530_CR3","doi-asserted-by":"publisher","unstructured":"Picazo JJ (2021) Vacuna frente al COVID-19 [Vaccine against COVID-19]. Rev Esp Quimioter. Spanish. https:\/\/doi.org\/10.37201\/req\/085.2021.","DOI":"10.37201\/req\/085.2021"},{"key":"5530_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9111740","author":"R Kandimalla","year":"2021","unstructured":"Kandimalla R, Chakraborty P, Vallamkondu J, Chaudhary A, Samanta S, Reddy PH, De Feo V, Dewanjee S (2021) Counting on COVID-19 vaccine: insights into the current strategies, progress and future challenges. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines9111740","journal-title":"Biomedicines"},{"key":"5530_CR5","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2021.1971569","author":"LI Kozlovskaya","year":"2021","unstructured":"Kozlovskaya LI, Piniaeva AN, Ignatyev GM, Gordeychuk IV, Volok VP, Rogova YV, Shishova AA, Kovpak AA, Ivin YY, Antonova LP, Mefyod KM, Prokosheva LS, Sibirkina AS, Tarasova YY, Bayurova EO, Gancharova OS, Illarionova VV, Glukhov GS, Sokolova OS, Shaitan KV, Moysenovich AM, Gulyaev SA, Gulyaeva TV, Moroz AV, Gmyl LV, Ipatova EG, Kirpichnikov MP, Egorov AM, Siniugina AA, Ishmukhametov AA (2021) Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies. Emerg Microbes Infect. https:\/\/doi.org\/10.1080\/22221751.2021.1971569","journal-title":"Emerg Microbes Infect"},{"key":"5530_CR6","unstructured":"WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) dashboard with vaccination data. https:\/\/covid19.who.int\/. Accessed 23 Feb 2022"},{"key":"5530_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.tig.2021.09.003","author":"A G\u00f3mez-Carballa","year":"2021","unstructured":"G\u00f3mez-Carballa A, Pardo-Seco J, Bello X, Martin\u00f3n-Torres F, Salas A (2021) Superspreading in the emergence of COVID-19 variants. Trends Genet. https:\/\/doi.org\/10.1016\/j.tig.2021.09.003","journal-title":"Trends Genet"},{"key":"5530_CR8","doi-asserted-by":"publisher","DOI":"10.32607\/actanaturae.11337","author":"AA Nikonova","year":"2021","unstructured":"Nikonova AA, Faizuloev EB, Gracheva AV, Isakov IY, Zverev VV (2021) Genetic diversity and evolution of the biological features of the pandemic SARS-CoV-2. Acta Nat. https:\/\/doi.org\/10.32607\/actanaturae.11337","journal-title":"Acta Nat"},{"key":"5530_CR9","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2021.62.11.961","author":"JY Choi","year":"2021","unstructured":"Choi JY, Smith DM (2021) SARS-CoV-2 variants of concern. Yonsei Med J. https:\/\/doi.org\/10.3349\/ymj.2021.62.11.961","journal-title":"Yonsei Med J"},{"key":"5530_CR10","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41562-021-01122-8","volume":"5","author":"E Mathieu","year":"2021","unstructured":"Mathieu E, Ritchie H, Ortiz-Ospina E et al (2021) A global database of COVID-19 vaccinations. Nat Hum Behav 5:947\u2013953. https:\/\/doi.org\/10.1038\/s41562-021-01122-8","journal-title":"Nat Hum Behav"},{"key":"5530_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-021-00974-0","author":"L Dupont","year":"2021","unstructured":"Dupont L, Snell LB, Graham C, Seow J, Merrick B, Lechmere T, Maguire TJA, Hallett SR, Pickering S, Charalampous T, Alcolea-Medina A, Huettner I, Jimenez-Guarde\u00f1o JM, Acors S, Almeida N, Cox D, Dickenson RE, Galao RP, Kouphou N, Lista MJ, Ortega-Prieto AM, Wilson H, Winstone H, Fairhead C, Su JZ, Nebbia G, Batra R, Neil S, Shankar-Hari M, Edgeworth JD, Malim MH, Doores KJ (2021) Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern. Nat Microbiol. https:\/\/doi.org\/10.1038\/s41564-021-00974-0","journal-title":"Nat Microbiol"},{"key":"5530_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41576-021-00408-x","author":"K Tao","year":"2021","unstructured":"Tao K, Tzou PL, Nouhin J, Gupta RK, de Oliveira T, Kosakovsky Pond SL, Fera D, Shafer RW (2021) The biological and clinical significance of emerging SARS-CoV-2 variants. Nat Rev Genet. https:\/\/doi.org\/10.1038\/s41576-021-00408-x","journal-title":"Nat Rev Genet"},{"key":"5530_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04266-9","author":"A Saito","year":"2021","unstructured":"Saito A et al (2021) Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. Nature. https:\/\/doi.org\/10.1038\/s41586-021-04266-9","journal-title":"Nature"},{"key":"5530_CR14","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab1041","author":"L Lu","year":"2021","unstructured":"Lu L, Mok BW, Chen LL, Chan JM, Tsang OT, Lam BH, Chuang VW, Chu AW, Chan WM, Ip JD, Chan BP, Zhang R, Yip CC, Cheng VC, Chan KH, Jin DY, Hung IF, Yuen KY, Chen H, To KK (2021) Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients. Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciab1041","journal-title":"Clin Infect Dis"},{"key":"5530_CR15","unstructured":"COVID-19 vaccine tracker and landscape. https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines. Accessed 23 Feb 2022"},{"key":"5530_CR16","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc1932","author":"Q Gao","year":"2020","unstructured":"Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, Li Y, Zhu L, Wang N, Lv Z, Gao H, Ge X, Kan B, Hu Y, Liu J, Cai F, Jiang D, Yin Y, Qin C, Li J, Gong X, Lou X, Shi W, Wu D, Zhang H, Zhu L, Deng W, Li Y, Lu J, Li C, Wang X, Yin W, Zhang Y, Qin C (2020) Development of an inactivated vaccine candidate for SARS-CoV-2. Science. https:\/\/doi.org\/10.1126\/science.abc1932","journal-title":"Science"},{"key":"5530_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30987-7","author":"Z Wu","year":"2021","unstructured":"Wu Z, Hu Y, Xu M, Chen Z, Yang W, Jiang Z, Li M, Jin H, Cui G, Chen P, Wang L, Zhao G, Ding Y, Zhao Y, Yin W (2021) Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60\u00a0years and older: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial. Lancet Infect Dis. https:\/\/doi.org\/10.1016\/S1473-3099(20)30987-7","journal-title":"Lancet Infect Dis"},{"key":"5530_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.06.008","author":"H Wang","year":"2020","unstructured":"Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W, Xu W, Zhao Y, Li N, Zhang J, Liang H, Bao L, Xu Y, Ding L, Zhou W, Gao H, Liu J, Niu P, Zhao L, Zhen W, Fu H, Yu S, Zhang Z, Xu G, Li C, Lou Z, Xu M, Qin C, Wu G, Gao GF, Tan W, Yang X (2020) Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell. https:\/\/doi.org\/10.1016\/j.cell.2020.06.008","journal-title":"Cell"},{"key":"5530_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02000-6","author":"R Ella","year":"2021","unstructured":"Ella R, Reddy S, Blackwelder W, Potdar V, Yadav P, Sarangi V, Aileni VK, Kanungo S, Rai S, Reddy P, Verma S, Singh C, Redkar S, Mohapatra S, Pandey A, Ranganadin P, Gumashta R, Multani M, Mohammad S, Bhatt P, Kumari L, Sapkal G, Gupta N, Abraham P, Panda S, Prasad S, Bhargava B, Ella K, Vadrevu KM, COVAXIN Study Group (2021) Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. Lancet. https:\/\/doi.org\/10.1016\/S0140-6736(21)02000-6","journal-title":"Lancet"},{"key":"5530_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101078","author":"K Zakarya","year":"2021","unstructured":"Zakarya K, Kutumbetov L, Orynbayev M, Abduraimov Y, Sultankulova K, Kassenov M, Sarsenbayeva G, Kulmagambetov I, Davlyatshin T, Sergeeva M, Stukova M, Khairullin B (2021) Safety and immunogenicity of a QazCovid-in\u00ae inactivated whole-virion vaccine against COVID-19 in healthy adults: a single-centre, randomised, single-blind, placebo-controlled phase 1 and an open-label phase 2 clinical trials with a 6\u00a0months follow-up in Kazakhstan. EClinicalMedicine. https:\/\/doi.org\/10.1016\/j.eclinm.2021.101078","journal-title":"EClinicalMedicine"},{"key":"5530_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2020.10.001","author":"C Liu","year":"2020","unstructured":"Liu C, Mendon\u00e7a L, Yang Y, Gao Y, Shen C, Liu J, Ni T, Ju B, Liu C, Tang X, Wei J, Ma X, Zhu Y, Liu W, Xu S, Liu Y, Yuan J, Wu J, Liu Z, Zhang Z, Liu L, Wang P, Zhang P (2020) The architecture of inactivated SARS-CoV-2 with postfusion spikes revealed by Cryo-EM and Cryo-ET. Structure. https:\/\/doi.org\/10.1016\/j.str.2020.10.001","journal-title":"Structure"},{"key":"5530_CR22","doi-asserted-by":"publisher","DOI":"10.36233\/0372-9311-136","author":"AV Gracheva","year":"2021","unstructured":"Gracheva AV, Korchevaya ER, Kudryashova AM, Borisova OV, Petrusha OA, Smirnova DI, Chernyshova IN, Svitich OA, Zverev VV, Faizuloev EB (2021) Adaptation of the MTT assay for detection of neutralizing antibodies against the SARS-CoV-2 virus. J Microbiol Epidemiol Immunobiol. https:\/\/doi.org\/10.36233\/0372-9311-136","journal-title":"J Microbiol Epidemiol Immunobiol"},{"key":"5530_CR23","doi-asserted-by":"publisher","DOI":"10.5501\/wjv.v5.i2.85","author":"MA Ramakrishnan","year":"2016","unstructured":"Ramakrishnan MA (2016) Determination of 50% endpoint titer using a simple formula. World J Virol. https:\/\/doi.org\/10.5501\/wjv.v5.i2.85","journal-title":"World J Virol"},{"key":"5530_CR24","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00310-20","author":"JF Chan","year":"2020","unstructured":"Chan JF, Yip CC, To KK, Tang TH, Wong SC, Leung KH et al (2020) Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp\/Hel real-time reverse transcription-PCR assay validated in vitro and with clinical specimens. J Clin Microbiol. https:\/\/doi.org\/10.1128\/JCM.00310-20","journal-title":"J Clin Microbiol"},{"key":"5530_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.joim.2021.09.001","author":"Y Yuan","year":"2021","unstructured":"Yuan Y, Wang RT, Xia J, Cao HJ (2021) Interventions for preventing influenza: an overview of Cochrane systematic reviews and a Bayesian network meta-analysis. J Integr Med. https:\/\/doi.org\/10.1016\/j.joim.2021.09.001","journal-title":"J Integr Med"},{"key":"5530_CR26","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1242539","author":"AL Stuurman","year":"2017","unstructured":"Stuurman AL, Marano C, Bunge EM, De Moerlooze L, Shouval D (2017) Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines\u2014a systematic review. Hum Vaccin Immunother. https:\/\/doi.org\/10.1080\/21645515.2016.1242539","journal-title":"Hum Vaccin Immunother"},{"key":"5530_CR27","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1285472","author":"NR Hegde","year":"2017","unstructured":"Hegde NR, Gore MM (2017) Japanese encephalitis vaccines: immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease. Hum Vaccin Immunother. https:\/\/doi.org\/10.1080\/21645515.2017.1285472","journal-title":"Hum Vaccin Immunother"},{"key":"5530_CR28","doi-asserted-by":"crossref","unstructured":"Vidor E, Plotkin SA (2013) Poliovirus vaccine\u2014inactivated. Vaccines, 6th edn. Elsevier Saunders, Philadelphia","DOI":"10.1016\/B978-1-4557-0090-5.00034-3"},{"key":"5530_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.01.015","author":"Y Xing","year":"2017","unstructured":"Xing Y, Schmitt HJ, Arguedas A, Yang J (2017) Tick-borne encephalitis in China: a review of epidemiology and vaccines. Vaccine. https:\/\/doi.org\/10.1016\/j.vaccine.2017.01.015","journal-title":"Vaccine"},{"key":"5530_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/BF02125526","author":"KE Schneweis","year":"1981","unstructured":"Schneweis KE, Gruber J, Hilfenhaus J, M\u00f6slein A, Kayser M, Wolff MH (1981) The influence of different modes of immunization on the experimental genital herpes simplex virus infection of mice. Med Microbiol Immunol. https:\/\/doi.org\/10.1007\/BF02125526","journal-title":"Med Microbiol Immunol"},{"key":"5530_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/BF01317862","author":"R Cappel","year":"1976","unstructured":"Cappel R (1976) Comparison of the humoral and cellular immune response after immunization with live, UV inactivated herpes simplex virus and a subunit vaccine and efficacy of these immunizations. Arch Virol. https:\/\/doi.org\/10.1007\/BF01317862","journal-title":"Arch Virol"},{"key":"5530_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.rvsc.2016.03.023","author":"Q Gao","year":"2016","unstructured":"Gao Q, Zhao S, Qin T, Yin Y, Yu Q, Yang Q (2016) Effects of inactivated porcine epidemic diarrhea virus on porcine monocyte-derived dendritic cells and intestinal dendritic cells. Res Vet Sci. https:\/\/doi.org\/10.1016\/j.rvsc.2016.03.023","journal-title":"Res Vet Sci"},{"key":"5530_CR33","unstructured":"Zahorska R, Mazur N, Korbecki M (1978) Immunogenicity of UV-inactivated measles virus. Zentralbl Bakteriol Orig A. 240(4):424-30."},{"key":"5530_CR34","unstructured":"Selimov M, Aksenova T, Klyueva E, Gribencha L, Lebedeva I (1978) Evaluation of the inactivated tissue culture rabies vaccine from the Vnukovo-32 strain. Results of its industrial production and field use for post-exposure immunization of man. Dev Biol Stand. 40:57-62."},{"key":"5530_CR35","doi-asserted-by":"crossref","unstructured":"Marthas ML, Miller CJ, Sutjipto S, Higgins J, Torten J, Lohman BL, Unger RE, Ramos RA, Kiyono H, McGhee JR et al (1992) Efficacy of live-attenuated and whole-inactivated simian immunodeficiency virus vaccines against vaginal challenge with virulent SIV. J Med Primatol. 21(2-3):99-107.","DOI":"10.1111\/j.1600-0684.1992.tb00574.x"},{"key":"5530_CR36","unstructured":"Bresler S, Kolikov V, Katushkina N, Molodkin V, Friedman E, Zheleznova H, Malafeieva L, Peradze T, Beljakov V, Ivanov K (1975) Immunogenicity of inactivated influenza vaccine, purified by adsorption chromatography on porous glas. Med Biol. 53(6):456-61."},{"key":"5530_CR37","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00983-14","author":"N Iwata-Yoshikawa","year":"2014","unstructured":"Iwata-Yoshikawa N, Uda A, Suzuki T, Tsunetsugu-Yokota Y, Sato Y, Morikawa S, Tashiro M, Sata T, Hasegawa H, Nagata N (2014) Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB\/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine. J Virol. https:\/\/doi.org\/10.1128\/JVI.00983-14","journal-title":"J Virol"},{"key":"5530_CR38","doi-asserted-by":"publisher","first-page":"13804","DOI":"10.1038\/s41598-021-93231-7","volume":"11","author":"CW Lo","year":"2021","unstructured":"Lo CW, Matsuura R, Iimura K et al (2021) UVC disinfects SARS-CoV-2 by induction of viral genome damage without apparent effects on viral morphology and proteins. Sci Rep 11:13804. https:\/\/doi.org\/10.1038\/s41598-021-93231-7","journal-title":"Sci Rep"},{"key":"5530_CR39","doi-asserted-by":"publisher","DOI":"10.1159\/000490567","author":"AM Mathew","year":"2018","unstructured":"Mathew AM, Mun AB, Balakrishnan A (2018) Ultraviolet inactivation of Chikungunya virus. Intervirology. https:\/\/doi.org\/10.1159\/000490567","journal-title":"Intervirology"},{"key":"5530_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2004.06.006","author":"ME Darnell","year":"2004","unstructured":"Darnell ME, Subbarao K, Feinstone SM, Taylor DR (2004) Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV. J Virol Methods. https:\/\/doi.org\/10.1016\/j.jviromet.2004.06.006","journal-title":"J Virol Methods"},{"key":"5530_CR41","unstructured":"List of Classifications\u2014IARC monographs on the identification of carcinogenic hazards to human. https:\/\/monographs.iarc.who.int\/list-of-classifications. Accessed 23 Feb 2021"},{"key":"5530_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2020.07.031","author":"CS Heilingloh","year":"2020","unstructured":"Heilingloh CS, Aufderhorst UW, Schipper L, Dittmer U, Witzke O, Yang D, Zheng X, Sutter K, Trilling M, Alt M, Steinmann E, Krawczyk A (2020) Susceptibility of SARS-CoV-2 to UV irradiation. Am J Infect Control. https:\/\/doi.org\/10.1016\/j.ajic.2020.07.031","journal-title":"Am J Infect Control"},{"key":"5530_CR43","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc4730","author":"H Gu","year":"2020","unstructured":"Gu H, Chen Q, Yang G et al (2020) Adaptation of SARS-CoV-2 in BALB\/c mice for testing vaccine efficacy. Science. https:\/\/doi.org\/10.1126\/science.abc4730","journal-title":"Science"},{"key":"5530_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3001284","author":"A Muruato","year":"2021","unstructured":"Muruato A, Vu MN, Johnson BA, Davis-Gardner ME, Vanderheiden A, Lokugamage K, Schindewolf C, Crocquet-Valdes PA, Langsjoen RM, Plante JA, Plante KS, Weaver SC, Debbink K, Routh AL, Walker D, Suthar MS, Shi PY, Xie X, Menachery VD (2021) Mouse-adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge. PLoS Biol. https:\/\/doi.org\/10.1371\/journal.pbio.3001284","journal-title":"PLoS Biol"},{"key":"5530_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/v13112263","author":"R Kant","year":"2021","unstructured":"Kant R, Kareinen L, Smura T, Freitag TL, Jha SK, Alitalo K, Meri S, Sironen T, Saksela K, Strandin T, Kipar A, Vapalahti O (2021) Common laboratory mice are susceptible to infection with the SARS-CoV-2 beta variant. Viruses. https:\/\/doi.org\/10.3390\/v13112263","journal-title":"Viruses"},{"key":"5530_CR46","unstructured":"National Research Council (US) (2011) Committee for the update of the guide for the care and use of laboratory animals. Guide for the Care and Use of Laboratory Animals. 8th ed. Washington (DC): National Academies Press (US); 2011."}],"container-title":["Archives of Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-022-05530-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00705-022-05530-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-022-05530-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T03:43:46Z","timestamp":1665632626000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00705-022-05530-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,20]]},"references-count":46,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["5530"],"URL":"https:\/\/doi.org\/10.1007\/s00705-022-05530-7","relation":{},"ISSN":["0304-8608","1432-8798"],"issn-type":[{"value":"0304-8608","type":"print"},{"value":"1432-8798","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,20]]},"assertion":[{"value":"22 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All applicable international, national, and\/or institutional guidelines for the care and use of animals, including the Guide for the Care and Use of Laboratory Animals [], were followed. This study was approved by the Medical Ethics Review Committee of the I. I. Mechnikov Research Institute of Vaccines and Sera (Ethics Committee Decision No 2 dated May 24, 2021).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}